Sarepta’s DMD Gene Therapy Helped Across Accelerated Approval Finish Line By CBER’s Peter Marks

 
• By Sue Sutter
Finish line
Elevidys crossed the finish line for a smaller population of patients than Sarepta would have liked. • Source: Shutterstock

More from Approvals

More from Product Reviews